Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06475898

Longitudinal Endpoint Assessment of Disease Burden in HD

LEAD-HD is intended to collect and analyze self-reported health information from individuals with Huntington Disease (HD) or prodromal HD participating in a 24-month longitudinal natural history study using remote technologies.

Recruiting

Interested in participating?

Request Info

Key information

About this study

The LEAD-HD study will be offered via HSG's online observational research platform called myHDstory®. This direct to patient study will collect and analyze self-reported health information from individuals with Huntington Disease (HD) or prodromal HD in a 24-month longitudinal natural history study that participants complete at any time and with their own electronic device.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Be 18 years of age or older;
  • Be willing and able to provide informed consent electronically;
  • Self-report, when answering as a participant, that you have been diagnosed with HD by a doctor, or have undergone genetic testing and been found to carry the gene mutation responsible for HD but have not been clinically diagnosed with HD (prodromal HD);
  • Have the ability to answer online questions or direct someone else to enter answers for them;
  • Have the ability to ambulate independently and take care of some of your personal needs;
  • Have the ability to read and understand English;
  • Be willing to create a unique identifier based on personal demographic information;
  • Reside in the United States or its territories. Surveys can only be completed in the US. If you move outside of the US, you will no longer be able to participate;
  • Own or have access to an electronic device and secure internet connectivity

Exclusion criteria

-

Treatment and study plan

Primary outcomes

  1. PRO natural history

    Time frame: December 2026

    Obtain PRO natural history data in HD.

  2. Demographic characteristics

    Time frame: December 2026

    Identify demographic characteristics that are associated with faster or slower disease progression.

  3. Assess the ability to consent and enroll

    Time frame: December 2026

    Assess the ability to consent and enroll participants in long-term longitudinal studies in HD using a direct-to-patient platform.

Study contacts

Contact information is provided by the study sponsor or research team.

Lauren Falanga

CONTACT

[email protected]

800-487-7671

Sponsors and collaborators

Lead sponsor

Huntington Study Group

Network

Collaborators

  • Modality.AI, Inc
  • Neurotargeting LLC
  • University of Rochester Center for Health + Technology

Registry information

Acronym: LEAD-HD

Important dates

Study start
2024
Primary completion
2026
Study completion
2026
First posted
Jun 26, 2024
Registry last updated
Sep 10, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.